Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 17/20 | 1.00 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634561 | 0.85 | KCNH2 (1.00) | KCNH2CACNA1IALDH1A1 | |
| SCHEMBL5634558 | 0.85 | KCNH2 (1.00) | KCNH2CACNA1IALDH1A1 | |
| SCHEMBL5635892 | 0.85 | KCNH2 (1.00) | KCNH2CACNA1IALDH1A1 | |
| SCHEMBL5634420 | 0.83 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5633512 | 0.83 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5634182 | 0.82 | KCNH2 (0.93) | KCNH2ALDH1A1 | |
| SCHEMBL11932013 | 0.80 | KCNH2 (0.89) | KCNH2CACNA1I | |
| SCHEMBL5634468 | 0.77 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5634641 | 0.77 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5634644 | 0.77 | KCNH2 (1.00) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | claimed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | KCNH2 33/4885CACNA1I 3/4885CCR2 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.